The baroreflex (BR) reflects autonomic blood pressure control. Alzheimer's disease (AD) affects the autonomic system. Detailed properties of BR in AD are unknown. We hypothesized that BR is reduced in AD, and is influenced by autonomic effects of cholinesterase inhibitors (ChEI). BR was determined in 18 AD patients, 11 patients with mild cognitive impairment (MCI) and 19 healthy control subjects. In AD, BR was measured again after ChEI treatment. Receiver operating characteristic analysis was used to define a BR cutoff value, which was then tested in an independent validation sample of 16 AD, 18 MCI, and 18 control subjects. BR was lower in AD compared with MCI (p < 0.05) and in MCI compared with healthy control subjects (p < 0.01). Receiver operating characteristic analysis between AD and healthy control subjects yielded a sensitivity of 89% and a specificity of 94%. ChEI treatment increased BR with 66% (p < 0.01). BR was reduced in AD and increased after treatment with ChEI. BR might be a good biomarker to further explore the link between cardiovascular disease and AD.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is the leading cause of dementia. Worldwide, AD is among the top 5 of most costly diseases and places a huge burden on individual caregivers (Burns, 2000) . There is still a limited understanding of this disease and its underlying cause, which is reflected in the lack of an effective curative treatment for AD.
Many of the currently developed and tested therapies are based on the amyloid cascade hypothesis. This hypothesis, supported by convincing genetic data, proposes that the extensive neuronal damage in AD is caused by increased concentration and aggregation of b-amyloid (Hardy and Higgins, 1992) . However, this theory does not offer an explanation for how this process is initiated in sporadic forms of AD, nor for the observation that the earliest changes in AD do not include amyloid deposition (Korczyn, 2008) . Criticism regarding the amyloid hypothesis has fueled the popularity of the vascular hypothesis for AD, which states that cardiovascular disease is an important causal or contributing factor in sporadic AD (Iwamoto et al., 2003; Newman et al., 2005; Snowdon et al., 1997; White et al., 2002) .
Although cardiovascular factors are now commonly accepted as risk factors for AD, the exact relationship between these factors and AD remains poorly understood. For example, midlife hypertension increases AD risk and antihypertensive treatment potentially reduces this risk (in't Veld et al., 2001; Launer et al., 2000) , suggesting a unidirectional, possibly causal relationship between hypertension and AD. However, subjects with a parental history of sporadic AD are more likely to have hypertension than control subjects (van Exel et al., 2009 ), suggesting either a causal relationship between AD and hypertension or a shared causative factor. Moreover, blood pressure (BP) levels decline from hypertension to normotension or even to hypotension during the course of AD (Skoog et al., 1996) . These data imply a relationship wherein AD might influence BP or BP might influence AD. Better understanding of the relationship between BP control and AD might therefore provide important new clues toward our understanding, and ultimately, treatment, of AD.
A possible link between AD and BP is the baroreflex (BR). The BR is a reflex loop with cardiac, vascular, and cerebral components involved in short-term BP regulation (Lantelme et al., 2002) . The BR operates via the autonomic nervous system to restore sudden changes in BP by changing heart rate (HR) or vascular tone. A clinical example is the drop in BP on standing, which the BR corrects by a rapid increase in HR (parasympathetic inhibition) followed by peripheral arterial vasoconstriction (sympathetic activation). The cholinergic system is an important component of cardiovascular and autonomic control, including the BR. This cholinergic system is prominently affected early in AD (Perry et al., 1977; Whitehouse et al., 1981) . Therefore, we hypothesized that BR function is reduced early in patients with AD (Medina et al., 1997) .
In this study, we further explored this hypothesis in 3 steps. First, we compared BR function between patients with AD, patients with mild cognitive impairment (MCI), and healthy elderly subjects. Patients with MCI are thought to represent patients with very earlystage AD. The second step was to validate our findings in an independent sample of AD patients, MCI patients, and elderly control subjects. The third and final step was to explore the role of the cholinergic deficit on BR function in AD, by testing the influence of cholinesterase inhibitors on BR function in a subgroup of patients with AD.
Methods

Study population
Overall, this study included 34 patients with mild to moderate AD, 29 patients with MCI, and 37 healthy control subjects in 2 distinct samples: (1) a derivation sample: 18 patients with AD (72 AE 6 years), 11 patients with MCI (71 AE 9 years), and 19 healthy control subjects (75 AE 3 years), recruited at Radboud University Nijmegen Medical Centre (RUNMC), and (2) a validation sample: 16 AD patients (71 AE 8 years), 18 patients with MCI (70 AE 7 years), and 18 healthy control subjects (70 AE 6 years) recruited at Maastricht University Medical Center (MUMC). Data on cerebral hemodynamics from the RUNMC AD patients and control subjects and from the MUMC AD and MCI patients and control subjects have been published recently (Gommer et al., 2012; van Beek et al., 2012) .
In both samples, recordings of electrocardiograms (ECG) and beat-to-beat photoplethysmographic BP were obtained. There was a difference in body position during measurements between the 2 samples. Subjects at RUNMC were seated while ECG and BP were recorded, whereas the subjects at MUMC were supine.
All subjects from both centers were examined by a geriatrician, and carefully screened to exclude acute medical conditions. A subset of subjects (15 control subjects; 15 MCI patients; 29 AD patients) had a magnetic resonance imaging scan of the brain to investigate medial temporal lobe atrophy. Informed consent was obtained from all patients and healthy control subjects before they entered the study. Both studies were approved by the medical ethical committees of the corresponding centers.
Patients with MCI and AD were diagnosed by a multidisciplinary memory clinic team using the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria (Blacker et al., 1994; McKhann et al., 1984) and MCI consensus criteria (Winblad et al., 2004 ) based on clinical evaluation and additional diagnostic tests if indicated, such as magnetic resonance imaging scan of the brain, neuropsychological testing, and cerebrospinal fluid analysis. In the derivation sample from RUNMC, BR in AD patients was measured before and after 8 weeks of treatment with a cholinesterase inhibitor (galantamine, 4 weeks of 8 mg followed by 4 weeks of 16 mg). In the validation sample from MUMC,10 of the 16 AD patients were already treated with cholinesterase inhibitors when BR was measured.
Data acquisition and preprocessing
The ECG was recorded using a 3-lead system and beat-to-beat HR was obtained from each R-R interval identified from the QRS complexes. Arterial BP was measured noninvasively at the middle finger of the right hand using Finapres (Finapres Medical Systems) at RUNMC and the Task Force Monitor (CN Systems) at MUMC. It has been shown that BP measured on the finger by photoplethysmography is similar to conventional auscultatory measurements on the upper arm (Imholz et al., 1991) . For both systems, the finger pressure cuff was positioned carefully at heart level with the hand being held in the left midaxillary line. The hand and arm were supported securely and comfortably with a sling. The subjects underwent several minutes of customization and the servo-adjust mechanism was turned off before recording. Periods of 100 seconds of artifact-and calibration-free data were selected by visual inspection of the time series of the tachogram and systogram and used for subsequent analysis. The time series were linearly interpolated at 1 Hz to obtain equidistant time intervals. The time series were detrended and filtered with an eighth-order high-pass Butterworth filter (0.02 Hz), to ascertain signal stationarity.
Causal model BR estimation
BR sensitivity is often evaluated noninvasively by assessing heart rate variability (HRV) and systolic blood pressure (SBP) variability. However, studies using HRV and SBP variability often report contradictory results (Allan et al., 2007; Collins et al., 2012; Zulli et al., 2005) . A possible explanation for this inconsistency is that the estimation of the BR by means of HRV assumes but does not test that the whole R-R interval (RRi) variability is generated by SBP changes. Therefore the causal dependencies are not taken into account. In this study, a bivariate causal model (ARXAR model), which was first introduced by Nollo et al. (2001) , was used to quantify the BR. With this model it is possible to describe the causal relationship from SBP to R-R interval (the BR pathway) and to separate it from the mechanical pathway (from RRi to SBP). Details of this method are described elsewhere .
In short, the interactions between R-R interval and systolic blood pressure (SBP) are modeled as follows:
According to the ARXAR model, the RR series is affected by p samples of its own past (by a k coefficients) and by p samples of the SBP sequence (by b k coefficients). The effects of other sources independent from SBP on R-R interval variability, considered as noise in this context, are accounted for in the model by means of the u(n). As outlined in Fig. 1 , the SBP and u signals are described as autoregressive processes with W SBP and W RRi zero-mean input white noises. The blocks C and D are formed by the autoregressive parameters of SBP and u, respectively. In the open loop ARXAR model the variability of SBP around its mean value is considered as an exogenous input (i.e., it might affect the R-R interval variability without itself being affected by the R-R interval variability). The coefficient estimation follows an iterative identification task based on the generalized least squares method. The model order p was chosen minimizing the Akaike figure of merit for the bivariate joint process jRRi SBPj . The gain of the R-R interval À SBP transfer function (G(f)) was estimated directly from the coefficients of the A and B blocks. The value of the gain in the low frequency band (0.04e0.15 Hz) was considered by sampling G(f) on the low frequency peak of the spectrum of the driving SBP series (Widesott et al., 2001) . It has been shown that there is a good agreement of the causal model with the traditional phenylephrine test to determine baroreceptor responsiveness ).
Statistics
Results are presented as the mean AE SD or percentage, unless stated otherwise. Differences in baseline variables and BR between control subjects and patients were evaluated with the MannWhitney test for continuous variables and c 2 statistics for proportions. Sensitivity and specificity pairs for different BR values distinguishing the groups were determined. These sensitivity and specificity values were used to construct a receiver operating characteristic (ROC) curve, in which the optimal sensitivity and specificity combination is visualized. A p value < 0.05 was considered statistically significant.
Results
Derivation sample
Sample description
Eighteen AD patients (11 women),19 age-matched healthy control subjects (5 women), and 11 MCI patients (6 women) from RUNMC participated in this study and had the BR measured successfully. Table 1 summarizes the sample characteristics. AD and control subjects did not differ with respect to SBP. However, SBP in MCI patients was higher than in the healthy control subjects (p < 0.01).
BR function
BR function was calculated in correspondence with the peak in the power spectra of the SBP between 0.04 and 0.15 Hz (dashed line), the frequency range in which BR modulation of HR occurs.
Mean values of the BR gain obtained by the ARXAR model are shown in Fig. 2 . BR was lower in AD (1.4 AE 0.8 ms/mm Hg) compared with control subjects (6.4 AE 2.7 ms/mm Hg) (p < 0.01). BR in MCI (2.9 AE 0.7 ms/mm Hg) differed from both AD (p < 0.01) and control subjects (p < 0.01) and was in between the values for AD and control subjects. The area under the ROC curve for the relationship between AD and healthy elderly was 0.92 (Fig. 3) . With a threshold (cutoff point) of 3.2 ms/mm Hg for AD, sensitivity was 89% and specificity was 94%.
3.2. Validation sample 3.2.1. Sample description SBP and R-R interval data were obtained from 16 AD patients (9 women), 18 age-matched healthy control subjects (9 women), and 18 MCI patients (10 women) from MUMC. Table 1 summarizes their characteristics. In the derivation sample (RUNMC), MCI patients had higher SBP than healthy control subjects. This was not the case in the validation sample from MUMC. There were additional differences between the derivation and validation sample: the MUMC MCI group had lower SBP (133 mm Hg) than the RUNMC MCI group (152 mm Hg) (p ¼ 0.02) and the MUMC control group had a lower HR (58 bpm) compared with the RUNMC control group (62 bpm) (p ¼ 0.04).
BR function was calculated in the same way as for the derivation sample. Mean values for BR gain obtained by the ARXAR model are shown in Fig. 2 (dashed lines) . Also, BR was lower in AD (1.6 AE 1.3 ms/mm Hg) compared with healthy control subjects (3.6 AE 0.8 ms/mm Hg) (p < 0.01). BR gain in the MCI group (2.3 AE 1.4 ms/mm Hg) also was lower than in healthy control subjects (p < 0.01), and higher than AD (p ¼ 0.03). Application of the BR cutoff value of 3.2 ms/mm Hg, as it had been obtained in the derivation sample, yielded a sensitivity of 93% and a specificity of 78% for differentiating AD from healthy control subjects in this validation dataset (Table 2 ).
Cholinesterase inhibitors
In 18 AD patients (11 women) in the derivation sample, SBP and R-R interval data were obtained before and after treatment with cholinesterase inhibitors. After treatment with cholinesterase 
Age mean, y AE SD 75 AE 3 7 4 AE 9 7 2 AE 6 7 0 AE 6 7 0 AE 7 7 1 AE 8 Sex (male/female) 14/5 5/6 7/11 9/9 8/10 7/9 MMSE (0e30), mean AE SD 29 inhibitors, BR increased from 1.4 AE 0.8 ms/mm Hg to 2.4 AE 0.9 ms/mm Hg (p < 0.01). In the validation sample, no before and after cholinesterase inhibitor treatment comparisons were available, however in this sample, BR was higher in the 10 patients who were treated with cholinesterase inhibitors (2.0 AE 1.5 ms/mm Hg) compared with the 6 patients who were not treated (0.89 AE 0.4 ms/mm Hg) (p ¼ 0.02). Cholinesterase inhibitor-treated patients in the derivation sample had a slightly higher BR than those in the validation sample (p ¼ 0.03).
Discussion
The main finding of our study is that the BR function is lowered in patients with AD compared with age-matched control subjects. Our results are in agreement with the depressed BR sensitivity observed in 24 patients with AD (Szili-Torok et al., 2001). Our study adds to these observations by the addition of a group of patients with MCI, reflecting early-stage AD, by reproducing our findings in an independent sample, and by investigating the effect of cholinesterase inhibitors on BR. Furthermore, a more precise BR quantification method was used. The traditional sequence analysis used in the study of Szili-Törok et al. (2001) assumes, but not tests, that the whole R-R interval variability is generated by SBP changes. The method used in our study takes this causal dependency into account by dividing the R-R interval variability in SBP-related and SBP-unrelated parts.
The difference in BR function was so prominent that it was possible to distinguish patients with AD from control subjects by their BR function. The discriminatory value of BR was so strong that it achieved a performance that compares with or even exceeds that of current diagnostic biomarkers, such as cerebrospinal fluid analysis of amyloid b42. Indeed, a cutoff value for BR gain of 3.2 ms/mm Hg reached a sensitivity of 89% and a specificity of 94% to discriminate AD from control subjects in the derivation sample. For comparison, cerebrospinal fluid analysis of amyloid b42 has an ROC of 0.9, with a sensitivity of 93% and a specificity of 87% to discriminate AD from control subjects (Spies et al., 2010) . This discriminatory cutoff value for BR performed equally well in the independent validation sample with a sensitivity of 93% and a specificity of 78% for differentiating AD from healthy control subjects. Additionally, MCI patients had a BR value that was intermediate between control subjects and AD. A strength of our study is that these results were also confirmed in the independent validation sample.
These findings underscore the importance of exploring the underlying mechanism that explains this association between impaired BR functioning and AD. They raise the question whether AD pathology results in impaired BR functioning or whether impaired BR functioning contributes to (acceleration of) AD pathology.
Possible mechanism and consequence of the decreased BR in AD
The BR is the major feedback control system for BP. Primary afferent fibers from arterial baroreceptorsdin the carotid sinus and aortic archdsend information to the nucleus tractus solitarius in the medulla oblongata (Dampney et al., 2003) . From here, information is sent via interneurons to the hypothalamus or to higher Fig. 3 . Receiver operating characteristic curve analysis of the predictive value of baroreflex (BR) in distinguishing Alzheimer's disease patients from healthy control subjects. The area under the curve equals 0.92; 95% confidence interval is 0.84-1.00; p < 0.01. The square shows the optimal BR cutoff point at 3.2 ms/mm Hg resulting in a sensitivity of 89% and a specificity of 94%. Performance of the proposed baroreflex cutoff score to distinguish between Alzheimer's disease (AD) and healthy control subjects, in the validation sample. regions in the brainstem and forebrain (Loewy, 1990) , including the insular cortex (Sykora, 2009) . The insular cortex is a recognized site of autonomic cardiovascular control and BR-mediated autonomic cardiovascular function (Saleh and Connell, 1998) . In 1998, Braak and Braak (1998) demonstrated a hierarchical progression of AD pathology that includes the insular cortex in an early stage. This insular involvement might lead to changes in cardiovascular and autonomic control, and might consequently affect the BR (Saleh and Connell, 1998; Zhang et al., 1998) . Further circumstantial evidence is found in the effects of exercise. Exercise improves cardiovascular function and BR (Monahan et al., 2000) . Exercise has also been shown to lower the risk of AD (Buchman et al., 2012) . Although direct associations between exercise, BR, and AD risk have not been investigated, and BR could be no more than a marker of exercise, it can be hypothesized that BR function is part of the causal pathway that links exercise to reduced AD risk, or that augmented BR is a marker of beneficial effects of exercise on autonomic brain centers.
Here, we have also shown that treatment with cholinesterase inhibitors augmented BR function in AD. This is in line with recent findings that atropine, in a dose which augments vagal tone, increased cardiovagal BR gain in older subjects (Callegaro and Taylor, 2012) . Our findings cannot be explained by age-related effects only (Gribbin et al., 1971) because we compared AD and MCI patients with age-matched healthy control subjects. Cholinesterase inhibitors partly compensate for the cholinergic deficit in AD. The cholinergic system has a pivotal role in learning and memory (Robinson et al., 2011) . However, the augmented BR function suggests that cholinesterase inhibitors might slow clinical disease progression not only through direct cognitive effects but also through their influence on cardiovascular factors such as BP regulation.
Our findings might extend to preclinical and early clinical AD, for example, patients with MCI. Patients with MCI have a high risk of progression to dementia, particularly of the Alzheimer type (Rasquin et al., 2005; Winblad et al., 2004) . There is a greater orthostatic fall in SBP in MCI and Alzheimer patients than in control subjects (Allan et al., 2007; Collins et al., 2012) and the prevalence of orthostatic hypotension in MCI patients lies between control subjects and AD patients (Mehrabian et al., 2010) . This observation parallels the BR values in control subjects, MCI, and AD found in our study and is in line with an earlier study which showed an association between blunted BR functioning and increased risk of orthostatic hypotension (La Rovere et al., 1998) .
Despite the fact that several studies have shown an association between AD and autonomic instability, such as increased pupillary dilatation (Grunberger et al., 1999) , diminished HR variability (Giubilei et al., 1998) , and orthostasis, the significance of the abnormalities in BR among AD patients is not yet fully known. However, impaired BR in other common dementia subtypes, such as Parkinson disease and Lewy body disease, is held partly responsible for the higher prevalence of orthostatic hypotension (Allan et al., 2007) and increased cardiovascular mortality. These patients also exhibit a significant loss of cholinergic forebrain neurons (Aarsland et al., 2004) .
BR functioning as a diagnostic tool
In the perspective of new therapeutic options to slow the progression of dementia, an early diagnosis of AD is of utmost importance because all treatment strategies are more effective in the earlier phases of the disease (Polak et al., 2007) . In this study, a rapid, noninvasive, and inexpensive procedure without need for active patient cooperation was used to estimate BR function from ECG and BP recordings, obtained when the patient quietly sits or lies down. Our results show that in patients with AD, a lowered BR could be a sensitive and specific marker of the disease. A strength of the study is the consistent decrease in BR found over the different groups (from healthy subjects to MCI patients to AD patients). This result points toward a disease-specific involvement of the BR. However, although we have shown that BR discriminates between AD and control subjects, further evidence must be obtained for its discriminatory value against important differential diagnoses in memory clinics (i.e., other causes of dementia and depression).
Limitations
Some methodological issues need to be considered. First of all, the diagnosis of AD and MCI in our study remains a clinical one. There was no pathologic confirmation of the underlying disease. However, previous studies have shown that a clinical diagnosis is only inaccurate, compared with pathologic diagnosis, in approximately 11% of mild cases (Salmon et al., 2002) . The patients with MCI and AD were diagnosed by a multidisciplinary memory clinic team consisting of several geriatricians, neuropsychologists, occupational therapists, and speech therapists. Lewy body dementia and vascular dementia were excluded based on diagnostic criteria for these conditions, using information obtained by means of history, clinical examination, laboratory tests, and additional, mostly radiologic, investigations. In a population referred to a memory clinic (as in this study), depending on criteria, a high percentage of MCI patients will develop AD (Palmer et al., 2007; Petersen et al., 2001 ). Still, in some patients MCI remains stable and never progresses to AD. Therefore the assumption that abnormal BR function serves as early detection of the Alzheimer disease process remains hypothetical. To overcome this limitation, larger scale studies with follow-up of MCI and AD patients are needed, with observations of BR during the different stages of progression of AD. Maybe a combination with other easy to determine parameters, in particular the cerebrovascular resistance index (Gommer et al., 2012) , could enhance discrimination of patients at risk for developing AD.
Second, it might be argued that results should have been corrected for differences in use of medication, because we included patients with comorbidities and medication. There is some information about whether commonly used antihypertensive agents, such as metoprolol and enalapril, can augment the cardiac autonomic function in hypertensive patients. Keeley et al. (1996) showed that b-blockers can directly improve cardiovascular autonomic regulation in normotensive and hypertensive patients (Keeley et al., 1996) . Further, Mancia et al. (1982) showed an increase in BR function when the circulating levels of angiotensin II and aldosterone were reduced by angiotensin-converting enzyme inhibitors. Because antihypertensive drugs mostly show an increase of the BR function, we argue that the difference in BR function between AD patients and healthy elderly would have been even greater when the AD patients had used no antihypertensive agents.
Third, some differences exist in population and protocol characteristics between the derivation and validation sample. In the validation sample the control subjects had a higher SBP (136 mm Hg compared with 125 mm Hg) than in the derivation sample. Furthermore, in the derivation sample BP and HR were obtained in the sitting position, in the validation sample BP and HR were obtained supine. These differences might explain the difference in BR between the 2 control groups (6.4 ms/mm Hg in the derivation sample versus 3.6 ms/mm Hg in the validation sample). Bristow et al. (1969) showed an inverse relationship between resting mean BP and BR, with reduced BR sensitivity in hypertension. This might explain the observed lower BR in the derivation sample where the SBP was higher. However, literature yields discordant results about the influence of posture on the BR results (Hartikainen et al., 1995; Wichterle et al., 2000) .
Finally, a limitation of the study is the cross-sectional design. This design allows us to establish the relationship between BR and AD, but we are unable to establish whether the impaired functioning of the BR is the effect or the cause of neurodegeneration.
Conclusions
This study shows a strong association between AD and diminished BR function. A possible link is the cholinergic system which is involved in both BR and AD. Cholinesterase inhibitors increase BR function in AD. Furthermore, MCI patients have an intermediate BR function between the normal and the AD subjects. Considering this, it is possible that early in AD besides cognition also BP regulation is affected. Further research on the relationship between BR and AD might provide valuable insights into the pathophysiology and for the diagnosis and treatment of AD.
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